VOLL MARK 4

What Happened
Mark Voll, Chief Financial Officer of RenovoRx, bought 25,000 shares of RenovoRx (RNXT) in an open-market purchase on May 19, 2026. The shares were acquired at $0.79 per share for a total cost of $19,690. This was a purchase (an acquisition), which insiders’ buys can be interpreted by investors as a direct investment in the company.

Key Details

• Transaction date and price: 2026-05-19 — 25,000 shares at $0.79 per share (total $19,690).
• Transaction type: P = Purchase (open market) (Footnote F1 confirms open-market purchases).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote F2: A prior grant of 58,953 RSUs for the CFO role was reported; as of April 30, 2026, 8,823 RSUs had vested and 50,130 remained unvested. RSUs vest monthly and are valued based on the closing price on the last trading day of the month.
• Filing timeliness: Report filed May 21, 2026 (two days after the trade date), consistent with typical Form 4 timing requirements.

Context

• This was a straightforward open-market purchase (code P). Purchases by officers are often watched by retail investors as a signal of personal investment, though filings alone do not reveal motivation.
• The RSU disclosure indicates additional future equity compensation subject to vesting; those unvested units are separate from the open-market purchase.